C3is Inc. Form 6-K Summary
Business Context and Reporting Period
C3is Inc., a Greek foreign private issuer, filed this Form 6-K for January 2024. The filing reports the closing of a firm-commitment underwritten public offering on January 23, 2024.
Offering and Key Financial Metrics
- The Company sold 28,000,000 units, comprising 6,660,000 common units and 21,340,000 pre-funded units.
- Each common unit included one common share, one-half of a Class B-1 Warrant and one Class B-2 Warrant.
- Each pre-funded unit included a pre-funded warrant, one-half of a Class B-1 Warrant and one Class B-2 Warrant.
- Class B-1 Warrants have an exercise price of $0.375 per common share, subject to an alternative cashless exercise option. Class B-2 Warrants have an exercise price of $0.425 per share.
- Gross offering proceeds were approximately $7.0 million before underwriting discounts and other estimated offering expenses. Net proceeds are not provided in the filing text.
- The underwriter partially exercised its over-allotment option for 2,100,000 additional Class B-1 Warrants and 4,200,000 additional Class B-2 Warrants.
- As of January 23, 2024, 28,307,840 common shares were outstanding, following the exercise of 12,965,000 pre-funded warrants.
Capitalization and Potential Dilution
- Pre-funded warrants remained outstanding for 8,375,000 common shares at an exercise price of $0.01 per share.
- Outstanding Class A Warrants covered up to 4,765,000 common shares at an exercise price of $1.05 per share.
- Outstanding Class B-1 Warrants covered up to 16,100,000 common shares, and Class B-2 Warrants covered up to 32,200,000 common shares.
- The Company also had 600,000 Series A Convertible Preferred Shares outstanding, with a $25.00 liquidation preference per share and a $0.25 conversion price, subject to adjustment.
Material Changes, Outlook, and Risks
The filing does not provide operating results, revenue, profit, cash flow, margins, debt, liquidity balances, or management guidance. It also does not compare results with a prior period.
The principal disclosed change is the completion of the approximately $7.0 million gross equity and warrant financing. Investors should consider potential dilution from the pre-funded warrants, Class A and Class B warrants, and convertible preferred shares. The filing states that the underwriter had a 45-day over-allotment option for additional securities, although only a partial exercise is reported as of January 23, 2024.
Important Facts to Verify
- Net cash proceeds after underwriting discounts, commissions, and offering expenses.
- Use of proceeds and the Company’s post-offering liquidity position.
- The detailed exercise, cashless exercise, adjustment, and expiration provisions of each warrant class.
- The potential fully diluted share count, including all warrants and convertible preferred shares.
- Whether the remaining over-allotment option was exercised after the filing date.